Chongqing Zhifei Biological Products Co.,Ltd. (300122.SZ): CA111 Injection Receives Clinical Trial Approval

Stock News09-17

Chongqing Zhifei Biological Products Co.,Ltd. (300122.SZ) announced that its controlling subsidiary, Chongqing Chen'an Biopharmaceutical Co., Ltd. ("Chen'an Bio"), has received a clinical trial approval notice from the National Medical Products Administration for its CA111 injection, permitting clinical trials in overweight or obese adult patients.

According to the announcement, Chen'an Bio's CA111 injection is a dual agonist targeting both glucose-dependent insulinotropic polypeptide (GIP) receptors and glucagon-like peptide-1 (GLP-1) receptors. GIP is a 42-amino acid gastrointestinal regulatory peptide that plays a physiological role in glucose homeostasis by stimulating insulin secretion from pancreatic β-cells in the presence of glucose and protecting pancreatic β-cells. GLP-1 is a 37-amino acid peptide that stimulates insulin secretion and protects pancreatic β-cells while inhibiting glucagon secretion, gastric emptying, and food intake, thereby controlling blood glucose and body weight.

The GIP and GLP-1 dual receptor agonist can achieve synergistic complementary effects by activating both GIP and GLP-1 receptors, resulting in enhanced glucose-lowering and weight reduction efficacy.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1109871979?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-17 17:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1109871979","market":"hk","top_or_hot":-1,"title":"Chongqing Zhifei Biological Products Co.,Ltd. (300122.SZ): CA111 Injection Receives Clinical Trial Approval","media":"Stock News","content":"<p>Chongqing Zhifei Biological Products Co.,Ltd. (300122.SZ) announced that its controlling subsidiary, Chongqing Chen'an Biopharmaceutical Co., Ltd. (\"Chen'an Bio\"), has received a clinical trial approval notice from the National Medical Products Administration for its CA111 injection, permitting clinical trials in overweight or obese adult patients.</p>\n<p>According to the announcement, Chen'an Bio's CA111 injection is a dual agonist targeting both glucose-dependent insulinotropic polypeptide (GIP) receptors and glucagon-like peptide-1 (GLP-1) receptors. GIP is a 42-amino acid gastrointestinal regulatory peptide that plays a physiological role in glucose homeostasis by stimulating insulin secretion from pancreatic β-cells in the presence of glucose and protecting pancreatic β-cells. GLP-1 is a 37-amino acid peptide that stimulates insulin secretion and protects pancreatic β-cells while inhibiting glucagon secretion, gastric emptying, and food intake, thereby controlling blood glucose and body weight.</p>\n<p>The GIP and GLP-1 dual receptor agonist can achieve synergistic complementary effects by activating both GIP and GLP-1 receptors, resulting in enhanced glucose-lowering and weight reduction efficacy.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chongqing Zhifei Biological Products Co.,Ltd. (300122.SZ): CA111 Injection Receives Clinical Trial Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChongqing Zhifei Biological Products Co.,Ltd. (300122.SZ): CA111 Injection Receives Clinical Trial Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-09-17 17:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Chongqing Zhifei Biological Products Co.,Ltd. (300122.SZ) announced that its controlling subsidiary, Chongqing Chen'an Biopharmaceutical Co., Ltd. (\"Chen'an Bio\"), has received a clinical trial approval notice from the National Medical Products Administration for its CA111 injection, permitting clinical trials in overweight or obese adult patients.</p>\n<p>According to the announcement, Chen'an Bio's CA111 injection is a dual agonist targeting both glucose-dependent insulinotropic polypeptide (GIP) receptors and glucagon-like peptide-1 (GLP-1) receptors. GIP is a 42-amino acid gastrointestinal regulatory peptide that plays a physiological role in glucose homeostasis by stimulating insulin secretion from pancreatic β-cells in the presence of glucose and protecting pancreatic β-cells. GLP-1 is a 37-amino acid peptide that stimulates insulin secretion and protects pancreatic β-cells while inhibiting glucagon secretion, gastric emptying, and food intake, thereby controlling blood glucose and body weight.</p>\n<p>The GIP and GLP-1 dual receptor agonist can achieve synergistic complementary effects by activating both GIP and GLP-1 receptors, resulting in enhanced glucose-lowering and weight reduction efficacy.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0188","symbol_name":"融资融券","start_time":0,"source_url":"","article_id":"1109871979","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1109871979","pubTimestamp":1758102265,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Chongqing Zhifei Biological Products Co.,Ltd. (300122.SZ) announced that its controlling subsidiary, Chongqing Chen'an Biopharmaceutical Co., Ltd. (\"Chen'an Bio\"), has received a clinical trial...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300122":"智飞生物","BK0188":"融资融券","LU2580892789.USD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (USD) ACC","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","BK0196":"行业龙头","BK0077":"质押式回购","BK0046":"生物疫苗","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","LU2580892862.HKD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (HKD) ACC","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","BK0239":"医药制造","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC"},"translate_title":"重庆智飞生物制品有限公司。（300122.SZ）：CA111注射液获临床试验批件","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300122":1},"content_text":"Chongqing Zhifei Biological Products Co.,Ltd. (300122.SZ) announced that its controlling subsidiary, Chongqing Chen'an Biopharmaceutical Co., Ltd. (\"Chen'an Bio\"), has received a clinical trial approval notice from the National Medical Products Administration for its CA111 injection, permitting clinical trials in overweight or obese adult patients.\nAccording to the announcement, Chen'an Bio's CA111 injection is a dual agonist targeting both glucose-dependent insulinotropic polypeptide (GIP) receptors and glucagon-like peptide-1 (GLP-1) receptors. GIP is a 42-amino acid gastrointestinal regulatory peptide that plays a physiological role in glucose homeostasis by stimulating insulin secretion from pancreatic β-cells in the presence of glucose and protecting pancreatic β-cells. GLP-1 is a 37-amino acid peptide that stimulates insulin secretion and protects pancreatic β-cells while inhibiting glucagon secretion, gastric emptying, and food intake, thereby controlling blood glucose and body weight.\nThe GIP and GLP-1 dual receptor agonist can achieve synergistic complementary effects by activating both GIP and GLP-1 receptors, resulting in enhanced glucose-lowering and weight reduction efficacy.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1109871979","isCrawlerRequest":true}